Sarepta Therapeutics (NASDAQ: SRPT) announced Friday it intends to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001.Sarepta ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE